Avalo Therapeutics, Inc. · Brief

Next report

5 days

Nov 5 · before openest.Q3 FY26

Expected move

±17.9%implied · report alone

5.898.45

straddle ±18.7%

spot 7.17exp Nov 20ATM strike 7.5ATM straddle 1.58IV 111%

Oct 30 closereport share · term structure

Expected move

—≥ implied

Q2 FY26±19.6%▼−0.74%×0.04

quarterimplied−20%0+20%realized×

Q2 FY26±19.6%▼−0.74%×0.04

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 5 report · est.

Bull2 of 3

5disclosed supplier and customer ties in SEC filingsSEC filings

4tracked funds holding AVTXN-PORT · Aug 31 '26

Bear1

0.35%of State Street SPDR S&P Biotech ETF assets as the largest tracked fund weightN-PORT · Jun 30 '26

AI captions · Oct 26 '26once per report · top 2 per case

AVTX report session

No linked exposure.

Oct 22impliedImplied move: ±24.2% into Nov 5 earnings (Oct 22 close).Source

Oct 22haltTrading halt: 09:31 ET, resumed 09:36 ET.Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.